Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Inclusion Criteria7

• Male patients aged ≥ 18 years old;
• Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing;
• Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages);
• High-aggressive disease (Gleason 8-10);
• High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis);
• Availability of source medical documentation;
• Known HRRm status based on tumour sample evaluation performed in routine practice.